Education
About Us
Working with TipRanks
Follow Us
Roche Holding AG (GB:0QOK)
LSE:0QOK
0QOK Stock Chart & Stats
CHF363.60
CHF8.64(3.34%)
At close: 4:00 PM EST
CHF363.60
CHF8.64(3.34%)
Day’s Range― - ―
52-Week RangeCHF221.30 - CHF377.00
Previous CloseN/A
Volume341.09K
Average Volume (3M)433.97K
Market Cap
$295.18B
Enterprise ValueCHF320.97B
Total Cash (Recent Filing)$15.48B
Total Debt (Recent Filing)$31.64B
Price to Earnings (P/E)23.1
Beta0.75
Next Earnings
Jul 23, 2026EPS Estimate
10.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.38
Shares Outstanding702,562,700
10 Day Avg. Volume520,275
30 Day Avg. Volume433,969
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)7.73
Price to Sales (P/S)4.25
P/FCF Ratio18.55
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue5.22
Enterprise Value/Gross Profit7.10
Enterprise Value/Ebitda14.17
Forecast
1Y Price Target
$345.34Price Target Upside-5.02% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)20.28
Revenue Forecast (FY)$62.96B
Bulls Say, Bears Say
Bulls Say
Adjuvant Market OpportunityGiredestrant's activity in hormone receptor–positive, HER2‑negative disease combined with a favorable tolerability profile creates potential to capture a substantial adjuvant breast cancer market currently constrained by toxic therapies.
Diagnostics Technology GrowthA suite of diagnostics innovations—including a high‑speed genetic sequencing platform, a proprietary sensor chip, and an automated mass spectrometry workflow—can drive scalable growth and help offset pressure from pharmaceutical patent expiries.
Unmet Need From TolerabilityA better‑tolerated oral selective estrogen receptor degrader presents an attractive alternative for patients and clinicians who avoid CDK4/6 inhibitor combinations because of toxicity and monitoring burdens, supporting broader endocrine therapy uptake.
Bears Say
Analyst Skepticism From Past Trial FailuresA track record of several high‑risk trials with negative outcomes has fostered analyst caution, which may restrain stock momentum until consistent late‑stage successes are demonstrated.
Clinical And Safety UncertaintiesRemaining questions about endocrine sensitivity in first‑line use and limited clarity on fenebrutinib's liver safety and statistical strength of results keep trial risk elevated and could weigh on clinical confidence.
Evidence And Regulatory Hurdles For CombinationsAdoption of giredestrant alongside CDK4/6 inhibitors may require definitive randomized trials, creating evidence and regulatory hurdles that could limit combined regimen uptake.
Roche Holding AG News
0QOK FAQ
What was Roche Holding AG’s price range in the past 12 months?
Roche Holding AG lowest share price was CHF221.30 and its highest was CHF377.00 in the past 12 months.
What is Roche Holding AG’s market cap?
Roche Holding AG’s market cap is $295.18B.
When is Roche Holding AG’s upcoming earnings report date?
Roche Holding AG’s upcoming earnings report date is Jul 23, 2026 which is in 146 days.
How were Roche Holding AG’s earnings last quarter?
Roche Holding AG released its earnings results on Jan 29, 2026. The company reported CHF8.375 earnings per share for the quarter, missing the consensus estimate of CHF8.515 by -CHF0.14.
Is Roche Holding AG overvalued?
According to Wall Street analysts Roche Holding AG’s price is currently Overvalued.
Does Roche Holding AG pay dividends?
Roche Holding AG does not currently pay dividends.
What is Roche Holding AG’s EPS estimate?
Roche Holding AG’s EPS estimate is 10.76.
How many shares outstanding does Roche Holding AG have?
Roche Holding AG has 702,562,700 shares outstanding.
What happened to Roche Holding AG’s price movement after its last earnings report?
Roche Holding AG reported an EPS of CHF8.375 in its last earnings report, missing expectations of CHF8.515. Following the earnings report the stock price went up 1.883%.
Which hedge fund is a major shareholder of Roche Holding AG?
Currently, no hedge funds are holding shares in GB:0QOK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.
0QOK Company Deck
0QOK Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted strong growth in pharmaceutical sales and robust pipeline development, particularly in oncology and neurology. However, challenges in the Diagnostics segment due to China's pricing reforms and mixed clinical trial results tempered the positive outlook. Additionally, regulatory setbacks and geopolitical uncertainties added caution.View all GB:0QOK earnings summaries0QOK Stock 12 Month Forecast
Average Price Target
CHF345.34
▼(-5.02% Downside)
Technical Analysis
Options Prices
Currently, No data available
---